Increased maternal serum aquaporin‐9 expression in pregnancies complicated with early‐onset preeclampsia

Objective. The aim of this study was to determine whether maternal serum matrix metalloproteinases 2, 3, 9, and 13 levels differ in early- and late-onset preeclampsia and uncomplicated pregnancies. Patients and Methods. The study was carried out in 125 pregnant women (29 with early-onset preeclampsia; 31 preeclamptic patients with late-onset preeclampsia; and 65 healthy pregnant controls). Levels of MMP-2, MMP-3, MMP-9, and MMP-13 were measured in the maternal serum using an enzyme-linked immunosorbent assay. Results. Maternal serum MMP-2 levels in both the groups of preeclamptic women were significantly higher than those in the controls. Levels of MMP-3 were significantly higher in preeclamptic patients with early-onset disease; however, the MMP-3 levels in patients with late-onset preeclampsia were similar to those observed in the control subjects. MMP-9 levels were lower whereas the levels of MMP-13 were higher in both preeclamptic groups of pregnant women than in the healthy controls, but these differences were statistically insignificant. Conclusions. One important finding of the present study was that MMP-3 appears to be involved solely in early-onset preeclampsia, but not in late-onset preeclampsia. Higher levels of MMP-2 and MMP-13 and lower levels of MMP-9 seem to be related to both early- and late-onset severe preeclampsia.

Download Full-text

Different Profile of Serum Leptin between Early Onset and Late Onset Preeclampsia

Disease Markers ◽

10.1155/2014/628476 ◽

2014 ◽

Vol 2014 ◽

pp. 1-7 ◽

Cited By ~ 15

Author(s):

Saeedeh Salimi ◽

Farzaneh Farajian-Mashhadi ◽

Anoosh Naghavi ◽

Mojgan Mokhtari ◽

Mahnaz Shahrakipour ◽

...

Keyword(s):

Early Onset ◽

Significant Positive Correlation ◽

Late Onset ◽

Maternal Serum ◽

Serum Adiponectin ◽

Enzyme Linked Immunosorbent Assay ◽

Serum Leptin ◽

Positive Correlation ◽

Early Onset Preeclampsia

Aim. This study was designed to clarify the role of leptin and adiponectin in preeclampsia (PE) pathogenesis and different subtypes of preeclampsia.Method. This case control study was performed in 45 PE patients and 45 healthy controls matched for age, BMI, and ethnicity. Serum leptin and adiponectin levels were determined by enzyme linked immunosorbent assay (ELISA).Results. Maternal serum leptin and adiponectin were significantly higher in PE women than controls. Serum leptin was elevated in early onset preeclampsia (EOPE) and late onset preeclampsia (LOPE) compared to controls. Among PE patients, serum leptin was higher in EOPE than LOPE women. However, serum adiponectin was not different between EOPE and LOPE women. The serum leptin was significantly higher in severe PE than mild PE. The serum adiponectin was significantly elevated in severe PE compared to controls. Significant positive correlation was observed between leptin and adiponectin and also between leptin and BMI in controls. Moreover significant positive correlation was observed between adiponectin and BMI in PE patients and controls.Conclusion. The present study showed that serum leptin level may play a significant role as a biomarker to differentiate early and late onset PE and also its relation to BMI and severity of disease.

Download Full-text

Effect of esomeprazole on maternal serum soluble fms-like tyrosine kinase-1 and endoglin in patients with early-onset preeclampsia

Proceedings in Obstetrics and Gynecology ◽

10.17077/2154-4751.28690 ◽

2021 ◽

Vol 99 (1) ◽

Author(s):

Ahmed M Abbas ◽

Yousra M Othman ◽

Mohamad M Abdallah ◽

Noura H. Abd Ellah ◽

Hanan G. Abdel Azim ◽

...

Keyword(s):

Placebo Group ◽

Tyrosine Kinase ◽

Early Onset ◽

Serum Levels ◽

Maternal Serum ◽

Termination Of Pregnancy ◽

Elisa Testing ◽

Significant Difference ◽

Fetal Complications ◽

Early Onset Preeclampsia

Objective: This study evaluates the effect of esomeprazole on the maternal serum levels of soluble fms-like tyrosine kinase-1 (sFlt-1) and soluble endoglin (sEng) in patients with early-onset preeclampsia.Methods: A randomized, double-blind, placebo-controlled trial was carried out in a tertiary University hospital between March 2018, and September 2019 (Clinical Trials.Gov: NCT03213639). The study included women between 28 and 31+6 weeks gestational age who had been diagnosed as preeclampsia without severe features. They were randomly assigned in a 1:1 ratio into an esomeprazole group, which received esomeprazole 40 mg orally once a day, and a placebo group, which received one placebo tablet daily. Blood samples were obtained to assess levels of serum sFlt-1and sEng using ELISA testing. The primary outcome was the difference between the mean serum level of sFlt-1 and sEng at the start of treatment and at the termination of pregnancy in both groups.Results: Eighty-eight patients were randomly assigned into both groups (44 in each). No statistically significant difference was found in the levels of sFlt-1 between both groups at admission and termination of pregnancy. The number of days of treatment for the esomeprazole group was slightly longer than the placebo group (11.4Â±9.4 vs. 10.3Â±6.3 days, P=0.515). No statistically significant difference in the rate of maternal and fetal complications occurred between the two groups. No side effects from the study medications were reported.Conclusions: Esomeprazole, at the dosage used in this study did not effectively lower the serum levels of sFlt-1 and sEng in patients with early-onset preeclampsia. Furthermore, it did not prolong the duration of pregnancy, nor did it decrease maternal or fetal complications.

Download Full-text

Second-trimester maternal serum placental growth factor and vascular endothelial growth factor for predicting severe, early-onset preeclampsia

Obstetrics and Gynecology ◽

10.1016/s0029-7844(03)00338-7 ◽

2003 ◽

Vol 101 (6) ◽

pp. 1266-1274 ◽

Cited By ~ 81

Author(s):

B Polliotti

Keyword(s):

Vascular Endothelial Growth Factor ◽

Growth Factor ◽

Early Onset ◽

Maternal Serum ◽

Placental Growth Factor ◽

Vascular Endothelial ◽

Second Trimester ◽

Early Onset Preeclampsia ◽

Endothelial Growth Factor

Download Full-text

Outcomes of Early-onset Preeclampsia With Severe Features at the University Hospital in Southern Thailand: a 15-year Experience

10.21203/rs.3.rs-182687/v1 ◽

2021 ◽

Author(s):

Noppasin Khwankaew ◽

Rapphon Sawaddisan ◽

Chitkasaem Suwanrath ◽

Alan Geater

Keyword(s):

Serum Creatinine ◽

Early Onset ◽

Elevated Serum ◽

Maternal Diabetes ◽

Maternal Serum ◽

Adverse Outcomes ◽

Gestational Age At Delivery ◽

Early Onset Preeclampsia ◽

Serum Aminotransferases ◽

Maternal Diabetes Mellitus

Abstract Purpose: To evaluate outcomes and factors associated with adverse outcomes among patients with early-onset preeclampsia with severe features at Songklanagarind Hospital. Methods: A retrospective study of 326 singleton women with early-onset preeclampsia with severe features treated at Songklanagarind Hospital between 2004-2019 was conducted. Baseline characteristics, management and outcomes were reviewed. Multivariate logistic regression was used to evaluate predictors of adverse outcomes. Statistical significance was set at p < 0.05.Results: There were no maternal mortalities, with 3.1% stillbirths and 6.7% neonatal deaths. High maternal serum creatinine (OR 3.26, 95% CI 1.27-8.36, p = 0.01) was significantly associated with adverse maternal outcomes. Early gestational age at delivery [< 28 weeks (OR 16.63, 95% CI 6.95-39.80, p <0.01), 28-32 weeks (OR 3.24, 95% CI 1.54-6.85, p <0.01)], maternal diabetes mellitus (OR 5.62, 95% CI 1.43-22.06, p = 0.01), high maternal serum creatinine (OR 2.66, 95%CI 1.20-5.93, p = 0.02) and elevated serum aminotransferases (OR 2.26, 95% CI 1.19-4.29, p = 0.01) were associated with serious adverse perinatal outcomes.Conclusions: Early-onset preeclampsia with severe features had favorable outcomes. Maternal diabetes mellitus, high serum creatinine, elevated serum aminotransferases and early gestational age at delivery were factors associated with poor outcomes.

Download Full-text

Early Prediction of Preeclampsia

Obstetrics and Gynecology International ◽

10.1155/2014/297397 ◽

2014 ◽

Vol 2014 ◽

pp. 1-11 ◽

Cited By ~ 91

Author(s):

Leona C. Poon ◽

Kypros H. Nicolaides

Keyword(s):

Early Onset ◽

False Positive Rate ◽

Protein A ◽

First Trimester ◽

Maternal Serum ◽

Uterine Artery Doppler ◽

Maternal Risk ◽

Positive Rate ◽

First Trimester Of Pregnancy ◽

Early Onset Preeclampsia

Effective screening for the development of early onset preeclampsia (PE) can be provided in the first-trimester of pregnancy. Screening by a combination of maternal risk factors, uterine artery Doppler, mean arterial pressure, maternal serum pregnancy-associated plasma protein-A, and placental growth factor can identify about 95% of cases of early onset PE for a false-positive rate of 10%.

Download Full-text